What is the first choice for blood pressure treatment?

The Lancet

Volumn 394, Issue 10211, 2019, Pages 1782-1784

  Ives, Christopher W ^a   Oparil, Suzanne ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; THIAZIDE DIURETIC AGENT;

ALL CAUSE MORTALITY; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR MORTALITY; COUGHING; DEMENTIA; DRUG CHOICE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; KIDNEY DISEASE; MONOTHERAPY; NOTE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DRUG EFFECT; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 85074756246     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)32461-4     Document Type: Note

References (12)

1. Muntner, P, Carey, RM, Gidding, S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol 71 (2018), 109–118.
2. Whelton, PK, Carey, RM, Aronow, WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 138 (2018), e484–e594.
3. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2019, National Institute for Health and Care Excellence, London.
4. Williams, B, Mancia, G, Spiering, W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39 (2018), 3021–3104.
5. Musini, VM, Gueyffier, F, Puil, L, Salzwedel, DM, Wright, JM, Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev, 8, 2017, CD008276.
6. Suchard, MA, Schuemie, MJ, Krumholz, HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet, 2019 published online Oct 24 https://doi.org/10.1016/S0140-6736(19)32317-7.
7. Hripcsak, G, Duke, JD, Shah, NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 216 (2015), 574–578.
8. Walker, AM, Patrick, AR, Lauer, MS, et al. A tool for assessing the feasibility of comparative effectiveness research. Comp Effect Res 3 (2013), 11–20.
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002), 2981–2997.
10. Zanchetti, A, Crepaldi, G, Bond, MG, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS—a randomized double-blind trial. Stroke 35 (2004), 2807–2812.
11. Wing, LM, Reid, CM, Ryan, P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003), 583–592.
12. Head, ML, Holman, L, Lanfear, R, Kahn, AT, Jennions, MD, The extent and consequences of p-hacking in science. PLoS Biol, 13, 2015, e1002106.